DrugPatentWatch

Competitive intelligence on small-molecule drugs and the 80,000 patents covering them

Simple flat-rate subscription plans

Ultimate Plan

$495/ month or  $2,495/ year

Generic Name: atorvastatin calcium

Summary for Generic Name: atorvastatin calcium

Tradenames:3
Patents:5
Applicants:9
NDAs:10
Drug Master File Entries: see list55
Suppliers: see list16
Therapeutic Class:Cardiovascular Agents
Formulation / Manufacturing:see details

Pharmacology for Ingredient: atorvastatin calcium

Clinical Trials for: atorvastatin calcium

Atorvastatin Calcium in Preventing Metabolic Syndrome in Patients With Prostate Cancer Receiving Long-Term Androgen-Deprivation Therapy
Status: Withdrawn Condition: Recurrent Prostate Cancer; Stage I Prostate Cancer; Stage IIA Prostate Cancer; Stage IIB Prostate Cancer; Stage III Prostate Cancer; Stage IV Prostate Cancer

Bioequivalence Study of Atorvastatin Calcium Tablets, 40 mg of Dr. Reddy's Under Fed Conditions
Status: Completed Condition: Healthy

A Comparison of Atorvastatin and Glimepiride Fixed Dose Combination and Atorvastatin and Glimepiride Loose Combination in the Treatment of Patients With Type 2 Diabetes Mellitus
Status: Completed Condition: Diabetes Mellitus, Type 2

Bioequivalence Study of Atorvastatin Calcium Tablets, 40 mg Under Fasting Conditions
Status: Completed Condition: Healthy

Evaluation of Efficacy and Safety of Omacor, Co-Administered With Atorvastatin, in Subjects With Hypertriglyceridemia
Status: Completed Condition: Hypertriglyceridemia

A Phase I Prevention Study of Atorvastatin in Women at Increased Risk for Breast Cancer
Status: Completed Condition: Atypical Ductal Breast Hyperplasia; Breast Cancer; Ductal Breast Carcinoma in Situ; Lobular Breast Carcinoma in Situ

A Bioequivalence Study Comparing Irbesartan/Atorvastatin Combination Tablet With Coadministration of Irbesartan and Atorvastatin
Status: Completed Condition: Healthy

A Study to Determine the Bioequivalence of SCH 900068 Compared to Marketed Products (Protocol No. P07551)
Status: Completed Condition: Hyperlipidemia

Atorvastatin as GVHD Prophylaxis for Allogeneic Hematopoietic Cell Transplantation
Status: Recruiting Condition: Graft vs Host Disease

Comparison of the Efficacy and Safety of AtorVastatin mOnotherapy vs. Combination Atorvastatin/Fenofibric Acid
Status: Recruiting Condition: Mixed Hyperlipidemia

Courtesy of ClinicalTrials.org
See more clinical trials for this drug

Litigation for: ATORVASTATIN


Glossary
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Apotex Inc
ATORVASTATIN CALCIUM
atorvastatin calcium
TABLET;ORAL090548May 29, 2012RXNo<disabled>
Dr Reddys Labs Ltd
ATORVASTATIN CALCIUM
atorvastatin calcium
TABLET;ORAL091650Jul 17, 2012RXNo<disabled>
Dr Reddys Labs Ltd
ATORVASTATIN CALCIUM
atorvastatin calcium
TABLET;ORAL202357Jul 17, 2012RXNo<disabled>
Kudco Ireland
ATORVASTATIN CALCIUM
atorvastatin calcium
TABLET;ORAL091624Apr 5, 2013RXNo<disabled>
This preview shows a limited data set
Complete access is available with a Subscription
first patents previous patents next patents last patents

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000  2001  2002  2003  2004  2005  2006  2007  2008  2009 
 2010  2011  2012  2013 

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Connect with Social Media:

Follow DrugPatentWatch on Twitter Connect with DrugPatentWatch on Linkedin Drug Patents on LinkedIn

Copyright © 2002-2014 thinkBiotech LLC. ISSN: 2162-2639

Other thinkBiotech sites: BiotechUBiotechBlogJournal of Commercial Biotechnology

`abc